leadf
logo-loader
viewBioHarvest Sciences Inc.
(
CSE:BHSCOTC:CNVCF
)

BioHarvest Sciences says new manufacturing facility in Israel has successfully met certification requirements ahead of time

The company noted that the ISO9001 certification covers internationally recognized standards for quality assurance and management, and the ISO22000 (HACCP) certification ensures that the required quality control and quality management systems are in place across the end-to-end manufacturing process to ensure the highest product safety levels

Vinia bottle
Despite the challenges caused by the coronavirus (COVID19) to the global supply chain, the new factory was built in 12 months

BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) has announced that the new manufacturing facility in Israel has successfully met the Israeli Ministry of Health's ISO9001 and ISO22000 (HACCP) certification requirements ahead of time. 

The company noted that the ISO9001 certification covers internationally recognized standards for quality assurance and management, and the ISO22000 (HACCP) certification ensures that the required quality control and quality management systems are in place across the end-to-end manufacturing process to ensure the highest product safety levels. These two certifications are critical steps required prior to obtaining the GMP (Good Manufacturing Practices) certification from the Israeli Ministry of Health.

In a statement, Kobi Rosenzweig, VP of Operations at BioHarvest Sciences said: "I am delighted with the Company's ability to successfully pass the internationally recognized stringent quality requirements on its first attempt. Considering the speed at which this factory was built, this achievement is a testimony to the quality of the team and the ingenuity of the BioFarming technology. I thank our manufacturing partner Sugart and especially Ori Hahn, their CEO, for all the efforts exerted to deliver on such an aggressive schedule."

READ: BioHarvest Sciences says it has successfully scaled its cannabis cells with trichomes production by a factor of 250 times

Despite the challenges caused by the coronavirus (COVID19) to the global supply chain, the new factory was built in 12 months. The facility will have the capacity to produce over 20 tons/year of VINIA as well as other polyphenol-based products the company has in its innovation pipeline.

Pilot production of VINIA in the new facility is expected to begin by the end of September 2021, and the capacity will be steadily increased each month to meet the growing demands of VINIA's D2C and B2B business in Israel, USA and other global markets.

Ilan Sobel, CEO of BioHarvest Sciences added: "The manufacturing arm of BioHarvest is an integral part of the Company's biotech vision. As a biotech innovator we will continue to develop and manufacture new products across multiple verticals. We have implemented the industrial manufacturing blueprint of our BioFarming technology in 12 months. This accomplishment gives me enormous confidence in our ability to scale our technology as we add on new verticals, (as in the case of Cannabis), and to build manufacturing plants closer to local markets such as North America, if required."

Based in Vancouver British Columbia, BioHarvest Sciences is the developer and exclusive owner of the proprietary and patent-protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself.

The company's technology is non-GMO and has already been validated by VINIA, the red grapes cells functional food/dietary supplement produced and sold by the company. It plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA and other Super Fruit Nutraceutical products.

Further, by adapting this technology to the cannabis plant, and building adequate production capacity, BioHarvest Sciences' objective is to become a leading supplier of cannabis for both medicinal and legal recreational purposes.

Contact the author at jon.hopkins@proactiveinvestors.com

 

Quick facts: BioHarvest Sciences Inc.

Follow
CSE:BHSC

Price: 0.34 CAD

Market Cap: $146.71 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

BioHarvest Sciences able to achieve major milestone as company scales up...

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from with Proactive to share news the company has been able to successfully scaled its Cannabis cells with trichomes production by a factor of 250x and it is now growing Cannabis in medium-scale bioreactors. Sobel telling Proactive this...

3 weeks, 5 days ago

3 min read